Detalhe da pesquisa
1.
The state of art on the use of patient reported outcomes in migraine.
Curr Opin Neurol
; 37(3): 271-282, 2024 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38529698
2.
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
J Neurol Neurosurg Psychiatry
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777579
3.
Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
Cephalalgia
; 44(2): 3331024231222923, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307497
4.
Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
Cephalalgia
; 44(2): 3331024241230279, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416486
5.
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization.
J Headache Pain
; 25(1): 58, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637736
6.
Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population.
J Headache Pain
; 25(1): 21, 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38347485
7.
Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.
Ann Neurol
; 92(5): 846-859, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054144
8.
Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
Cephalalgia
; 43(8): 3331024231177636, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37555331
9.
Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome.
Eur J Neurol
; 30(7): 1937-1944, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37038303
10.
Migraine worsening after COVID-19 and COVID-19 vaccination: Are we facing a nocebo effect?
Eur J Neurol
; 30(12): 3877-3885, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37791410
11.
Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task.
J Headache Pain
; 24(1): 104, 2023 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545005
12.
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
J Headache Pain
; 24(1): 63, 2023 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37268904
13.
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
Cephalalgia
; 42(3): 186-196, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601944
14.
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
Headache
; 62(10): 1395-1405, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36321947
15.
Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period.
Cephalalgia
; 41(1): 45-57, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32838536
16.
Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study.
Eur J Neurol
; 28(7): 2378-2382, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730441
17.
Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
Headache
; 61(8): 1277-1280, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363619
18.
The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
Headache
; 61(9): 1403-1410, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601726
19.
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
J Headache Pain
; 22(1): 120, 2021 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620085
20.
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study.
J Headache Pain
; 22(1): 151, 2021 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903177